Related Experiment Videos

Association between plasma homocysteine concentration and carotid atherosclerosis in hemodialysis patients

T Sakurabayashi1, M Fujimoto, Y Takaesu

  • 1Kidney Center, Shinraku-en Hospital, Niigata, Japan. fm6y-kud@asahi-net.or.jp

Japanese Circulation Journal
|September 25, 1999
PubMed

Insights

High homocysteine levels (tHcy) in hemodialysis patients are linked to accelerated atherosclerosis. Advanced age, systolic hypertension, and smoking also significantly worsen this condition, impacting cardiovascular health.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Accelerated atherosclerosis is a significant complication for patients on long-term hemodialysis.
  • Hyperhomocysteinemia is a potential contributing factor to atherosclerosis in this population.

Purpose of the Study:

  • To investigate the association between plasma total homocysteine concentration (tHcy) and cardiovascular risk factors in hemodialysis patients.
  • To determine the relationship between tHcy and the extent of generalized atherosclerosis.

Main Methods:

  • 168 hemodialysis patients were assessed for plasma tHcy levels.
  • Carotid artery intimal-medial wall thickness (IMT) was measured using B-mode ultrasonography to indicate atherosclerosis.
  • Multiple regression analysis was employed to identify factors associated with carotid IMT.

Main Results:

  • Hemodialysis patients exhibited significantly higher tHcy levels (33.0+/-16.9 micromol/L) compared to healthy subjects.
  • Carotid maximum IMT was significantly associated with age, systolic blood pressure, smoking, duration of hemodialysis, and tHcy.
  • These five factors explained 36.0% of the variation in carotid maximum IMT.

Conclusions:

  • Hyperhomocysteinemia is a significant risk factor for accelerated atherosclerosis in chronic uremic patients.
  • The combination of hyperhomocysteinemia, advanced age, systolic hypertension, and smoking exacerbates atherosclerosis in this vulnerable group.
  • Factors such as gender, diastolic blood pressure, and lipid profiles were not found to be significantly related to atherosclerosis in this study.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...